The First Cholesterol Pill That Works Like an Injection Just

This article summarizes a recent FDA drug approval for informational purposes. It is not medical advice — decisions about cholesterol treatment should be made with a physician who can evaluate your specific health history and risk factors.

Key Takeaways

The FDA approved Lipfendra (enlicitide) on July 16, 2026 — the first-ever oral PCSK9 inhibitor, a drug class that has existed only as injectables since 2015.
In its pivotal trial, the once-daily pill reduced LDL ("bad") cholesterol by 56% compared with placebo at 24 weeks — performance that matches, not just approaches, existing injectable PCSK9 drugs.
Lipfendra's list price is roughly half that of Novartis's injectable Leqvio, and analysts project peak annual sales between $2 billion and $5 billion.
The drug requires a specific dosing routine — it must be taken with water, coffee, or tea, followed by a 30-minute wait before eating — which some physicians say could meaningfully affect real-world adherence.
It's not yet known whether Lipfendra reduces heart attacks or strokes directly; that question is being tested in an ongoing, separate cardiovascular outcomes trial.

What actually got approved, and why the FDA highlighted it specifically

The FDA's own July 16, 2026 announcement described Lipfendra (enlicitide) as the first oral inhibitor of PCSK9, approved as an add-on to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH) — an inherited condition that causes dangerously high cholesterol from a young age. PCSK9 is a protein produced by the liver that reduces the liver's ability to clear LDL cholesterol from the bloodstream; drugs that inhibit it help the body clear more LDL on its own. Since the first PCSK9 inhibitors — Amgen's Repatha and Regeneron/Sanofi's Praluent — reached the market in 2015, every drug in the class has required an injection. Lipfendra is the first available as a pill.

The approval was supported by two Phase 3 trials in Merck's CORALreef program, involving a combined 3,207 adults already on maximally tolerated statin therapy who still needed further LDL reduction. In the larger CORALreef Lipids trial (2,904 patients), Lipfendra produced a 56% placebo-adjusted reduction in LDL cholesterol at 24 weeks; in the CORALreef HeFH trial (303 patients with the inherited form of high cholesterol), the reduction was 59%. Those results are notable specifically because they're in the same range as existing injectable PCSK9 drugs — this isn't a weaker oral alternative to an established injectable, it's a pill matching the effectiveness of the treatment it's designed to replace for patients who prefer it.

Why cardiologists are calling this more than just a convenience upgrade

Dr. Ann Marie Navar, a cardiologist at UT Southwestern Medical Center and a lead author on the CORALreef studies, framed the approval's significance around who it's likely to reach, not just how it works: "An obvious patient group for enlicitide will be patients who are unable or unwilling to take an injection," she told Pharmacy Times, adding that she hopes the ease of prescribing an oral option will expand "the pool of clinicians adding on therapy after statins" — potentially helping close longstanding gaps in access to non-statin cholesterol treatment.

That access gap is well documented and long-standing. Injectable PCSK9 inhibitors have been available for over a decade, yet uptake has consistently lagged behind their clinical effectiveness — a pattern industry coverage attributes to a combination of price, insurance prior-authorization hurdles, and patient reluctance around self-injection. Cardiologist Vishal Khetpal, writing for STAT after the approval, described it as "a long-awaited moment in preventive cardiology," while also cautioning that the shift may not be immediate: "In truth, I don't anticipate prescribing patterns changing immediately." That measured framing — genuine clinical significance, paired with realistic expectations about how quickly prescribing habits actually shift — is a useful way to read the approval's near-term impact.

The dosing requirement that could matter more than it sounds like

Lipfendra comes with a specific administration requirement that distinguishes it from a typical once-daily pill: it must be taken with water, coffee, or tea, followed by a 30-minute wait before eating anything. That's a real behavioral ask, not a minor footnote — medication adherence research consistently shows that any added step in a daily routine reduces how consistently patients actually take a drug as prescribed, and a mandatory 30-minute food-free window is a more demanding requirement than most oral medications carry. Reporting on the approval flagged this specifically as a "downside" worth watching, since real-world effectiveness depends on patients actually following the regimen — a trial's controlled setting doesn't fully predict how a dosing requirement like this holds up over months or years of everyday use.

What's still unknown: this isn't yet proven to prevent heart attacks

It's important to be precise about what Lipfendra's approval does and doesn't establish. The FDA approval and the CORALreef trials measured LDL cholesterol reduction — a well-established surrogate marker strongly associated with lower cardiovascular risk — not direct reduction in heart attacks, strokes, or cardiovascular death. Merck has stated directly that it is not yet known whether Lipfendra reduces the risk of cardiovascular events, and a separate, ongoing cardiovascular outcomes trial is specifically designed to answer that question. Earlier injectable PCSK9 inhibitors did eventually demonstrate reduced cardiovascular events in their own outcomes trials, which is part of why LDL reduction from this drug class is taken seriously as a meaningful surrogate — but Lipfendra's own direct outcomes data doesn't yet exist, and that distinction matters for how confidently the drug's real-world benefit can currently be described.

Why this approval matters beyond cardiology, for Merck specifically

Lipfendra's approval carries real strategic weight for Merck as a company, which is worth understanding as separate context from the drug's clinical value. Merck's blockbuster cancer treatment Keytruda — which generated $31.7 billion, or 55% of the company's total revenue last year — is set to lose key patent protections starting in 2028, exposing the company to biosimilar competition. Analyst consensus places Lipfendra's peak annual sales potential between $2 billion and $5 billion, and the drug's approval was explicitly framed by Merck's own leadership as part of the company's broader pipeline diversification strategy. Lipfendra was also granted approval through the FDA's Commissioner's National Priority Voucher program, an initiative designed to accelerate review timelines for medicines aligned with specific public health priorities — making it the ninth drug approved through that program, according to BioSpace's tracking.

What this means if you or someone you know is managing high cholesterol

This is a new option, not a replacement for existing treatment plans. Lipfendra is approved as an add-on to diet, exercise, and statin therapy for people who need further LDL reduction — not a first-line replacement for statins, which remain the foundational treatment for most patients with high cholesterol.
The injection-averse patient population is the clearest immediate beneficiary. If a patient has previously avoided or discontinued an injectable PCSK9 inhibitor specifically because of the injection itself, this approval creates a genuinely new option worth discussing with a physician — not simply a marginal alternative to an existing injectable.
The dosing routine is a real commitment, not a minor detail. Anyone considering this medication should discuss the food-and-beverage timing requirement honestly with their doctor and think concretely about whether it fits their actual daily routine, since adherence to that specific requirement affects how well the drug can work as intended.
This is not yet proven to directly prevent heart attacks or strokes. Patients and physicians should treat the drug's LDL-lowering effect as strong evidence of likely cardiovascular benefit, consistent with the broader PCSK9 inhibitor class's track record, while recognizing that Lipfendra's own outcomes data is still pending.

Frequently Asked Questions

Is Lipfendra the same medication as Repatha or Praluent, just in pill form? No — while all three are PCSK9 inhibitors that work through the same general biological pathway, Lipfendra (enlicitide) uses a different drug technology (a macrocyclic peptide) than Repatha and Praluent (which are monoclonal antibodies), and it's a distinct, separately developed and separately approved medication, not a reformulated version of an existing drug.

How does Lipfendra's price compare to injectable PCSK9 inhibitors? Reporting on the approval indicates Lipfendra's list price is roughly half that of Novartis's newer injectable competitor, Leqvio — though actual out-of-pocket cost for any patient depends heavily on insurance coverage and formulary placement, which weren't fully established at the time of approval.

Who is heterozygous familial hypercholesterolemia (HeFH), and why does it matter for this approval? HeFH is an inherited genetic condition that causes significantly elevated LDL cholesterol from birth, substantially raising the risk of early cardiovascular disease. Lipfendra's approval specifically covering HeFH patients matters because this population often requires more aggressive, combination cholesterol treatment than the general hypercholesterolemia population, and has historically had fewer treatment options.

What were the most common side effects reported in the trials? In the CORALreef HeFH trial, diarrhea occurred in 7% of Lipfendra patients versus 2% on placebo, and dizziness occurred in 9% versus 4% on placebo. Overall adverse-event and treatment-discontinuation rates were reported as similar between the Lipfendra and placebo groups across both trials.

When will it be known whether Lipfendra actually reduces heart attacks and strokes? Merck has an ongoing dedicated cardiovascular outcomes trial evaluating this specific question, though a completion or results timeline wasn't specified in coverage of the approval. Until that trial reports results, Lipfendra's cardiovascular benefit is inferred from its LDL-lowering effect and the broader PCSK9 inhibitor class's established outcomes track record, rather than demonstrated directly for this specific drug.

Sources & References

U.S. Food and Drug Administration, "FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults With High Cholesterol" (July 16, 2026)
Merck & Co., Inc., official press release and Q2 2026 Form 8-K filing
Pharmacy Times, "FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol"
STAT News, "Barriers may keep Merck's new cholesterol drug from success"
FiercePharma, "FDA approves an oral PCSK9 med for 1st time in Merck's Lipfendra"
CNN, "Merck's cholesterol pill gets US FDA approval"
BioSpace, "Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor"

The First Cholesterol Pill That Works Like an Injection Just Got FDA Approval